We used the E2A-PBX B-cell acute lymphoblastic leukemia cell line as an easily accessible B cell model and treated them with a MDM2 inhibitor, fixed them, and stained them with DAPI and anti-phospho NF-κB antibody. This evidence concerns the gene NFKB1 and acute lymphoblastic leukemia.